Valuation: IGM Biosciences, Inc.

Market Cap 76.57M 66.98M 61.78M 57.06M 108M 7.3B 110M 738M 290M 3.6B 288M 281M 12.37B P/E 2023
-1.76x
P/E 2024 -1.89x
Enterprise Value -62.03M -54.26M -50.05M -46.22M -87.7M -5.92B -89.18M -598M -235M -2.91B -233M -228M -10.02B EV / Sales 2023
88,302,162x
EV / Sales 2024 83,883,966x
Free-Float
56.71%
Yield 2023 *
-
Yield 2024 -
1 year 1.25
Extreme 1.25
1.36
3 years 0.92
Extreme 0.92
22.5
5 years 0.92
Extreme 0.92
93.98
10 years 0.92
Extreme 0.92
133
Manager TitleAgeSince
Chief Executive Officer - 2025-08-13
Chief Tech/Sci/R&D Officer - 2017-12-31
Chief Operating Officer - -
Date Insider Type Main position Quantity % Market Cap.
25-08-13Issuer sale

Director

54,235 0.1592%
25-08-13
Topsøe Holding A/S
Issuer saleCompany 10,400,564 30.5206%
25-08-13
Redmile Group LLC
Issuer saleCompany 7,199,325 23.5788%
Change 5-day change 1-year change 3-year change Capi.($)
-2.31%-.--%-6.62%-87.87% 76.57M
+1.84%-0.66%+59.82%+92.96% 54.88B
-4.14%-8.06%+58.96%+118.67% 54.63B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.87B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
+8.74%+3.51%+51.91%+726.40% 15.75B
-1.05%+1.16%+25.95%+194.27% 14.2B
Average -0.84%-0.25%+46.20%+183.56% 24.16B
Weighted average by Cap. -0.90%-1.45%+51.25%+177.05%

Financials

2023 2024
Net sales 2.13 1.86 1.72 1.59 3.01 203.15 3.06 20.53 8.06 100.08 8 7.82 344.04 2.68 2.34 2.16 2 3.79 255.51 3.85 25.83 10.14 125.87 10.06 9.84 432.72
Net income -246M -216M -199M -184M -348M -23.5B -354M -2.38B -933M -11.58B -925M -905M -39.8B -196M -171M -158M -146M -277M -18.67B -281M -1.89B -741M -9.2B -735M -719M -31.63B
Net Debt -297M -260M -240M -221M -420M -28.34B -427M -2.86B -1.12B -13.96B -1.12B -1.09B -48B -139M -121M -112M -103M -196M -13.22B -199M -1.34B -525M -6.51B -520M -509M -22.39B
Logo IGM Biosciences, Inc.
IGM Biosciences LLC, formerly known asIGM Biosciences, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing and delivering a new class of medicines to treat patients with cancer and autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites compared to conventional IgG antibodies with only two binding sites. It is also focused on creating, developing, manufacturing, and commercializing IgM antibody agonists against oncology and immunology and inflammation targets. The Company’s development programs include Aplitabart, Imvotamab, and IGM-2644. Aplitabart is an IgM antibody targeting Death Receptor 5 (DR5) proteins, being evaluated in multiple phase I combination trials for the treatment of colorectal cancer. Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins.
Employees
16
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. IGMS Stock